Key Developments For Dionex Corporation
Dionex Corporation (DNEX.O) (Nasdaq)
Dionex Corporation Issues Q2 2010 Guidance; Revenue Guidance Above Analysts' Estimates; Raises FY 2010 Guidance
Dionex Corporation announced that for second quarter of 2010, it expects net sales to be in the range of $107-$110 million and diluted earnings per share (EPS) to be in the range of $0.83-$0.87 per share, including the cost of goods sold for the write-up of acquired inventory from ESA. For fiscal 2010, it estimate that sales will be in the range of $408-$417 million and diluted earnings per share will be $3.08-$3.17. According to Reuters Estimates, analysts were expecting the Company to report revenues of $105 million and EPS of $0.86 for second quarter of 2010; revenues of $392 million and EPS of $3.09 for fiscal 2010.
Dionex Corporation Completes Acquisition Of Assets Of ESA Life Sciences Tools Business Unit
Dionex Corporation announced that it has completed the acquisition of HPLC products, HPLC clinical assays, laboratory services and related assets from ESA Biosciences pursuant to the purchase agreement signed on September 15, 2009.
Magellan Biosciences, Inc. Sells Its Life Sciences Tools Business To Dionex Corporation
Magellan Biosciences, Inc. announced that it has sold its ESA Life Sciences Tools (LST) business to Sunnyvale, California based Dionex Corporation. The sale includes all of ESA's HPLC related products, HPLC clinical assays, the ESA Laboratories services and assets, as well as ESA's headquarters in Chelmsford, Massachusetts. Financial terms of the transaction were not disclosed.
Dionex Corporation Enters Into Agreement With ESA Biosciences To Acquire Assets Of ESA Life Sciences Tools Business Unit
Dionex Corporation announced that it has entered into an asset purchase agreement with ESA Biosciences, a wholly owned subsidiary of Magellan Biosciences, Inc., to purchase ESA Biosciences HPLC products, HPLC clinical assays, laboratory services and related assets. This acquisition will add three category HPLC detector families to the Dionex HPLC product portfolio. The terms of the transaction were not disclosed. The transaction is expected to close by the end of September.
Dionex Corporation Issues Q1, FY 2010 Guidance; EPS Guidance Below Analysts' Estimates
Dionex Corporation announced that for first quarter of 2010, it expects net sales to be in the range of $85-$88 million and diluted earnings per share (EPS) to be in the range of $0.50-$0.54 per share. For fiscal 2010, it estimate that sales to be in the range of $385-$393 million and diluted EPS to be $3.01-$3.10. Among the assumptions on which our guidance is based are: currency rates will have a negative impact on sales for the first quarter with a slightly positive impact in the remaining quarters of fiscal 2010; gross margin will be in the range of 66-67% for fiscal 2010, as the one-time items in the fourth quarter of fiscal 2009 will not recur; operating expenses will increase slightly faster than sales due to our global IT initiatives, tax rate for fiscal year 2010 should be in the range of 34%-35%, and the current economic weakness will continue to affect our results for at least the first two quarters of fiscal year 2010 and anticipate some recovery in the second half of the fiscal year. According to Reuters Estimates, analysts were expecting the Company to report revenues of $93 million and EPS of $0.69 for first quarter of 2010; revenues of $385 million and EPS of $3.19 for fiscal 2010.
